Barclays
AGL icon

Barclays’s Agilon Health AGL Stock Holding History

Barclays’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$811K Buy
7,564
+2,101
+38% +$138K ﹤0.01% 2923
2026
Q1 		$43.2K Sell
5,463
-15,682
-74% -$254K ﹤0.01% 4375
2025
Q4 		$364K Buy
21,145
+1,500
+8% +$29.1K ﹤0.01% 4032
2025
Q3 		$506K Sell
19,645
-7,162
-27% -$271K ﹤0.01% 3806
2025
Q2 		$1.54M Buy
26,807
+7,985
+42% +$640K ﹤0.01% 3046
2025
Q1 		$2.04M Sell
18,822
-5,292
-22% -$461K ﹤0.01% 2617
2024
Q4 		$1.15M Sell
24,114
-25,044
-51% -$1.51M ﹤0.01% 3289
2024
Q3 		$4.83M Buy
49,158
+8,593
+21% +$1.11M ﹤0.01% 2122
2024
Q2 		$6.63M Buy
40,565
+21,870
+117% +$3.12M ﹤0.01% 1382
2024
Q1 		$2.85M Buy
18,695
+6,390
+52% +$1.06M ﹤0.01% 2275
2023
Q4 		$3.86M Sell
12,305
-606
-5% -$219K ﹤0.01% 2349
2023
Q3 		$5.73M Sell
12,911
-5,045
-28% -$2.28M ﹤0.01% 1250
2023
Q2 		$7.78M Buy
17,956
+17,427
+3,294% +$9.79M ﹤0.01% 1096
2023
Q1 		$314K Sell
529
-475
-47% -$266K ﹤0.01% 3555
2022
Q4 		$405K Sell
1,004
-2,594
-72% -$1.22M ﹤0.01% 3441
2022
Q3 		$2.11M Buy
3,598
+1,599
+80% +$957K ﹤0.01% 1711
2022
Q2 		$1.09M Buy
1,999
+1,593
+392% +$806K ﹤0.01% 2276
2022
Q1 		$258K Buy
+406
New +$209K ﹤0.01% 3271

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NPCM
North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Barclays's AGL Position: Q2 2026 in Review

Barclays increased its Agilon Health (AGL) stake by 38% in Q2 2026, buying an estimated $138K and bringing the position to 7,564 shares worth $811K. The position accounts for ﹤0.01% of the portfolio, ranked #2923.

Barclays first reported a position in AGL in Q1 2022 and has held it in 18 quarters since. The position peaked at $7.78M in Q2 2023. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

  • Barclays held 7,564 shares of Agilon Health worth $811K as of Q2 2026.
  • Barclays bought 2,101 Agilon Health shares in Q2 2026, an estimated $138K.
  • Agilon Health made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2923 holding.
  • Barclays first reported a position in Agilon Health in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Agilon Health position peaked at $7.78M in Q2 2023.
  • 179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.